Exelixis (EXEL) is a publicly traded Healthcare sector company. As of October 3, 2026, EXEL trades at $58.47 with a market cap of $14.47B and a P/E ratio of 32.32. EXEL moved +0.79% today. Year to date, EXEL is +33.98%; over the trailing twelve months it is +41.21%. Its 52-week range spans $32.38 to $61.14. Analyst consensus is neutral with an average price target of $52.00. Rallies surfaces EXEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for EXEL combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $58.47 |
| Market Cap | $14.47B |
| P/E Ratio | 32.32 |
| EPS | $1.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $61.14 |
| 52-Week Low | $32.38 |
| Volume | 1.35M |
| Avg Volume | 0 |
| Revenue (TTM) | $2.17B |
| Net Income | $521.27M |
| Gross Margin | 96.49% |
15 analysts cover EXEL: 0 strong buy, 4 buy, 10 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $52.00.